|
Showing 1 - 2 of
2 matches in All Departments
The imbalance between rapidly proliferating tumor cells and
inadequate and inefficient tumor vasculature leads to a decrease in
oxygen levels (hypoxia and/or anoxia) in tumor tissues. Intra-tumor
hypoxia profoundly affects the biological behavior of cancer cells,
which become resistant to conventional therapies and acquire a more
invasive and metastatic phenotype.Hypoxia is a hallmark of the
malignant phenotype and a key feature of the tumor
microenvironment. Hypoxia Inducible Factor 1 (HIF-1) is a master
regulator of the transcriptional response to oxygen deprivation.HIF
triggers the expression of genes whose products induce
angiogenesis, decrease oxygen consumption, switch metabolism to
glycolysis, maintain a stem cell phenotype and select for more
invasive and metastatic cells. Therapeutic approaches targeting
HIF, directly or downstream mediators of its transcriptional
activity, are being developed. Intra-tumor hypoxia is atopic
hasbeen gaining scientific interestover the last few years for its
wide involvement in many physiological and pathological processes.
This volume will cover the latest research and translational
aspects associated with intra-tumor hypoxia, along with
opportunities for drug development offered by this unique feature
of the tumor microenvironment. The ongoing efforts to translate our
understanding of the biology underlying intra-tumor hypoxia in
viable therapeutic options face many challenges, but this book will
provide an opportunity for an in-depth analysis of the fundamental
mechanisms implicated in the adaption to low oxygen levels and will
scrutinize the potential for opportunities that are being pursued
in both research and the drug development industry."
The imbalance between rapidly proliferating tumor cells and
inadequate and inefficient tumor vasculature leads to a decrease in
oxygen levels (hypoxia and/or anoxia) in tumor tissues. Intra-tumor
hypoxia profoundly affects the biological behavior of cancer cells,
which become resistant to conventional therapies and acquire a more
invasive and metastatic phenotype. Hypoxia is a hallmark of the
malignant phenotype and a key feature of the tumor
microenvironment. Hypoxia Inducible Factor 1 (HIF-1) is a master
regulator of the transcriptional response to oxygen deprivation.
HIF triggers the expression of genes whose products induce
angiogenesis, decrease oxygen consumption, switch metabolism to
glycolysis, maintain a stem cell phenotype and select for more
invasive and metastatic cells. Therapeutic approaches targeting
HIF, directly or downstream mediators of its transcriptional
activity, are being developed. Intra-tumor hypoxia is a topic has
been gaining scientific interest over the last few years for its
wide involvement in many physiological and pathological processes.
This volume will cover the latest research and translational
aspects associated with intra-tumor hypoxia, along with
opportunities for drug development offered by this unique feature
of the tumor microenvironment. The ongoing efforts to translate our
understanding of the biology underlying intra-tumor hypoxia in
viable therapeutic options face many challenges, but this book will
provide an opportunity for an in-depth analysis of the fundamental
mechanisms implicated in the adaption to low oxygen levels and will
scrutinize the potential for opportunities that are being pursued
in both research and the drug development industry.
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.